Report me for selling fake medicine? Why are you crying when your illness relapses?

"Mr. Chen, our offer is very sincere."

"If our expectations are met, your company's new drug will have a very good future."

"But this is only the first phase of clinical trials, and the risk of failure is still very high. Our acquisition of patents is also a gamble on the future. If it fails, we will lose everything."

Gao Tianlong immediately said, "Under the circumstances, our bid is already very sincere. I believe it will be difficult for your company to find a buyer who can offer higher than ours."

Gao Tianlong was a little dumbfounded by Chen Xuan’s refusal.

It was such a sincere and high price, which could be called a high price to buy, so why did you refuse it without even a moment of hesitation?

You know, 320 billion yuan is more than enough to acquire a medium-sized pharmaceutical company.

Antai Pharmaceutical Group is just a newly established pharmaceutical company, and it actually refused to agree to such a sky-high acquisition.

This really made him a little confused.

"That's what AbbVie thinks, but I don't think so."

"If a new drug hasn't started clinical trials yet, that's fine."

"In fact, clinical trials for new drugs have been going on for some time now, and I'm sure you're all familiar with the daily data."

Chen Xuan shook his head and said, "From the current reports, the success rate of new drugs being approved for marketing is very high, and almost all of them are performing better than expected."

The meaning of this statement is also a direct rebuttal to Gao Tianlong.

The lung cancer drug he mentioned is still in clinical trials and the failure rate remains high, which makes the acquisition very risky.

But in fact, the lung cancer specific drug has shown very good performance in various data during clinical trials.

The volunteers' condition was also better than expected, and they showed no adverse reactions.

Judging from these data, the success rate of lung cancer-specific drugs is already very high, and the chance of failure is very small.

AbbVie also treats its lung cancer-specific drug as an ordinary drug, and includes the risks of other drugs in it, which is a bit self-deception.

Gao Tianlong...

Faced with these remarks, he could not help but remain silent.

In fact, he also knew that what Chen Xuan said made sense. Abovit analyzed various data.

The conclusion is that the success rate of lung cancer-specific drugs is very high, with a probability of passing clinical trials of over 90%.

Given the indications and therapeutic effects of this drug, once it is launched on the market, it is very likely to become the new king of medicine and be crowned as a sales myth for many years. This is why AbbVie decided to acquire it.

It is because the lung cancer drug has great potential that they offered a price of 200 billion yuan.

It was obvious that Chen Xuan also knew this, and the price alone was not enough to impress him.

……

……

"Mr. Chen, how about you tell me your price?"

"How much would you ask for in exchange for the patent for the formula of a lung cancer drug?"

After a brief silence, Gao Tianlong spoke in the car, "Of course, this also includes Antai Pharmaceutical Group. You can also make an offer, and we will seriously consider it."

Chen Xuan was so powerful that he had no choice but to retreat.

Because he didn't know how much money it would take to satisfy Chen Xuan, it would be better to let the latter name the price himself.

As long as there is a price, everything is negotiable.

He can also report to the headquarters and then decide whether to agree to the acquisition conditions.

"I won't talk about Antai Pharmaceutical Group."

"I don't want to work for others, and I won't sell my shares in the company." Chen Xuan waved his hand.

The valuation of Antai Pharmaceutical Group is both easy and difficult to calculate.

It is convenient for all kinds of assets, and the prices can be estimated at a glance.

But what is difficult to calculate is how much he is worth as a person. There will never be a specific price for this.

After all, whether he can develop new drugs in the future will directly affect how much value he will have, and there is no way to know this in advance.